Summary
The product Equimed 250, manufactured by Deus Medical, underwent laboratory testing to verify its contents and dosage accuracy. The sample, identified by batch number CS25776 with a manufacturing date of October 2020, was tested for qualitative and quantitative parameters by Janoshik Analytical. The analysis confirmed the presence of boldenone undecylenate at a measured concentration of 261.90 mg/ml, exceeding the labeled claim of 250 mg/ml by 4.76%.
Testing was conducted on 19 November 2020, with the sample submitted and paid for by the reseller DEUSPOWER.SHOP. The findings demonstrate an accurate dosage close to the claimed specification, reflecting reliability and consistency.
Detailed Report
Product Overview
- Manufacturer: Deus Medical
- Product Name: Equimed 250
- Active Ingredient: Boldenone Undecylenate
- Batch Number: CS25776
- Manufacture Date: October 2020
- Delivery Method: Injectable (AAS oil)
Sample Acquisition and Testing
- Task Number: #09084
- Testing Ordered: 13 November 2020
- Sample Received: 18 November 2020
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: DEUSPOWER.SHOP (Reseller)
- Analysis Paid For By: DEUSPOWER.SHOP (Reseller)
Testing Results
- Specification: 250 mg/ml Boldenone Undecylenate (as stated on the label)
- Measured Concentration: 261.90 mg/ml
- Accuracy: 104.76% of the label claim
- Variance: +4.76%
Verification Details
- Verification URL: https://janoshik.com/tests/09084_TTZI3BISJ5FA
- Originally Published: https://thinksteroids.com/community/forums/analytical-lab-testing/
Evaluation of Reseller-Funded Testing
This analysis was funded and submitted by DEUSPOWER.SHOP, a reseller, which may introduce a potential for bias. Reseller-funded testing might involve selective sample submissions. However, Janoshik Analytical’s detailed testing methodology and reputation for accuracy lend credibility to the results. Users are encouraged to cross-reference this data with independent analyses when possible.
Conclusion
The analysis confirms that Equimed 250 by Deus Medical meets its label claim with a slight overdosage of boldenone undecylenate, ensuring consistency and quality. The findings offer valuable insights for educational and harm reduction purposes.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
